Scilex Holding Company Announces Approval of a New Drug Submission (NDS) from the Health Canadas Pharmaceutical Drugs Directorate, Bureau of Cardiology, Allergy and Neurological Sciences for ELYXYBs Acute Treatment of Migraine With or Without Aura in Cana
April 15, 2025 09:00 ET | Source: Scilex Holding Company ELYXYB® is…